Company WuXi AppTec Co., Ltd.

Equities

603259

CNE1000031K4

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 13/03/2026			5-day change	1st Jan Change
90.87 ^CNY	-1.13%		-1.71%	+0.25%

04/03	JPMorgan Chase's long position in H-shares of Wuxi Apptec increases to 8.32% on Feb 26 from 7.14%, HKEX shows	RE
20/02	BlackRock's long position in H-shares of Wuxi Apptec decreases to 4.51% on Feb 16 from 5.22%, HKEX shows	RE

Business description: WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd. specializes in providing a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and biotech industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. Net sales break down by activity as follows:

- laboratory services (60.9%): small molecules discovery services, bioanalytical services, medical devices safety testing services, comprehensive manufacturing and testing services for cell and gene therapies, etc.;

- CMO and CDMO services (31.9%): development of manufacturing processes, production of advanced intermediates and active pharmaceutical ingredients, formulation development and dosage drug product manufacturing, for preclinical and clinical trials, new drug application, and commercial supply of chemical drugs, etc.;

- clinical research services (7.1%): project planning, clinical operation and monitoring and managements of phase I-IV clinical trials, medical device trials, etc.;

- other (0.1%).

Net sales are distributed geographically as follows: China (25.1%), Asia (4.1%), the United States (53.6%), Europe (16%) and other (1.2%) .

Number of employees: 39,414

Sales by Activity: WuXi AppTec Co., Ltd.

Fiscal Period: December	2020 (CNY)	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)
Chemical Business	-	1.41TCr	2.88TCr	2.92TCr	2.91TCr
Test Business	-	452.51Cr	571.87Cr	653.97Cr	567.07Cr
Biology Business	-	198.51Cr	247.51Cr	255.26Cr	254.39Cr
High-end therapy CTDMO business (Wu Xi ATU)	-	102.64Cr	130.8Cr	130.96Cr	-
Clinical Research and Other CRO Services	116.89Cr	-	-	-	-
US District Laboratory Services	151.66Cr	-	-	-	-
Laboratory Services in China	854.58Cr	-	-	-	-
Unallocated Other	2.21Cr	2.75Cr	3.36Cr	4.1Cr	65Cr
Domestic New Drug Research and Development Service Unit (Wu Xi DDSU)	528.21Cr	125.1Cr	97Cr	73Cr	-

See all business segments

Geographical breakdown of sales: WuXi AppTec Co., Ltd.

Fiscal Period: December	2020 (CNY)	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)
Overseas	-	-	-	3.3TCr	3.09TCr
China	414.53Cr	580.2Cr	752.6Cr	733.05Cr	704.76Cr
Asia	68Cr	-	-	-	-
Rest of World	20Cr	123.4Cr	151.2Cr	-	-
Europe	265.08Cr	371.9Cr	443.2Cr	-	-
United States	886.19Cr	1.21TCr	2.59TCr	-	-

See all geographic segments

Executive Committee: WuXi AppTec Co., Ltd.

Manager	Title	Age	Since
Min Zhang Chen CEO	Chief Executive Officer	56	02/08/2021
Qing Yang CEO	Chief Executive Officer	57	21/05/2020
Ge Li CEO	Chief Executive Officer	58	06/06/2023
Zhao Hui Zhang LAW	General Counsel	56	01/12/2000
Ming Shi DFI	Director of Finance/CFO	51	01/01/2022

See WUXI APPTEC CO., LTD. governance

Composition of the Board of Directors: WuXi AppTec Co., Ltd.

Director	Title	Age	Since
Ge Li CHM	Chairman	58	01/12/2000
Zhao Hui Zhang BRD	Director/Board Member	56	01/12/2000
Min Zhang Chen BRD	Director/Board Member	56	06/05/2022
Harry He CHM	Chairman	60	15/07/2016
Min Fang Zhu BRD	Director/Board Member	55	11/03/2016
Xiao Meng Tong BRD	Director/Board Member	52	23/03/2016
Qing Yang BRD	Director/Board Member	57	15/05/2020
Bo Yang Wu BRD	Director/Board Member	62	31/08/2020
Yi Bing Wu BRD	Director/Board Member	57	23/03/2016
Shao Hua Lu-Wong BRD	Director/Board Member	57	31/05/2023

Composition of the Board of Directors

Shareholders: WuXi AppTec Co., Ltd.

Name	Equities	%	Valuation
Ge Li 19.06 %	48,78,64,151	19.06 %	6 975 M ¥
Shanghai Zhongmin Yinfu Capital Management Co. Ltd. 3.402 %	8,70,74,568	3.402 %	1 245 M ¥
Summer Bloom Investments (I) Pte Ltd. 3.313 %	8,47,92,526	3.313 %	1 212 M ¥
China Asset Management Co., Ltd. 2.998 %	7,67,28,001	2.998 %	1 097 M ¥
Zhong Ou Asset Management Co., Ltd 2.868 %	7,33,93,875	2.868 %	1 049 M ¥

Name	Equities	%	Valuation
Qatar Holding LLC 5.856 %	2,98,95,700	5.856 %	455 M ¥
Invesco Asset Management Ltd. 3.753 %	1,91,56,800	3.753 %	291 M ¥
Fidelity Management & Research Co. LLC 3.572 %	1,82,32,444	3.572 %	277 M ¥
Schroder Investment Management (Hong Kong) Ltd. 3.229 %	1,64,85,600	3.229 %	251 M ¥
UBS Asset Management Switzerland AG 2.88 %	1,47,03,873	2.88 %	224 M ¥

List of WUXI APPTEC CO., LTD. shareholders

Holdings: WuXi AppTec Co., Ltd.

Name	Equities	%	Valuation
WUXI XDC CAYMAN INC. 20.92%	26,32,00,000	20.92%	2 125 M $
SENSORION 1.02%	52,49,608	1.02%	2 M $

Company details: WuXi AppTec Co., Ltd.

WuXi AppTec Co., Ltd.

288 Fute Middle Road

200131, Shanghai

+86 21 5046 1111

http://www.wuxiapptec.com.cn

Group companies: WuXi AppTec Co., Ltd.

Name	Category and Sector
STA Pharmaceutical Hong Kong Ltd. STA Pharmaceutical Hong Kong Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals	Pharmaceuticals: Major

See all subsidiaries

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
WUXI APPTEC CO., LTD.	-1.13%	-1.71%	+47.54%	+13.28%	3.99TCr
ARGENX SE	-0.36%	-1.95%	+13.50%	+89.85%	4.35TCr
INSMED INCORPORATED	-0.01%	-0.45%	+85.83%	+661.46%	3.01TCr
BIONTECH SE	+1.21%	-10.16%	-6.44%	-29.73%	2.16TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.71%	-2.60%	+46.27%	-33.62%	1.86TCr
GENMAB A/S	-2.18%	-4.08%	+24.04%	-30.91%	1.65TCr
AKESO, INC.	-0.81%	+8.04%	+53.91%	+180.41%	1.31TCr
SUMMIT THERAPEUTICS INC.	+4.27%	+6.68%	-16.00%	+953.59%	1.2TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.75%	+6.76%	+68.43%	-	1.16TCr
EXELIXIS, INC.	+0.17%	-0.73%	+12.07%	+145.33%	1.07TCr
Average	+0.06%	-0.21%	+32.91%	+216.63%	2.17TCr
Weighted average by Cap.	-0.24%	-1.16%	+35.02%	+184.10%